DAS181
Parainfluenza Virus (PIV) in immunocompromised patients
Phase 3Active
Key Facts
Indication
Parainfluenza Virus (PIV) in immunocompromised patients
Phase
Phase 3
Status
Active
Company
About Ansun BioPharma
Ansun BioPharma is a private, pre-revenue biotech founded in 2011 and headquartered in San Diego, CA. The company is advancing a late-stage clinical pipeline targeting severe respiratory viral infections in immunocompromised patients, utilizing a platform based on sialic acid biology. With a seasoned board of directors and a lead asset in Phase 3, Ansun is positioned to address significant unmet medical needs in a high-risk patient population. The company's success hinges on the clinical and regulatory outcome of its pivotal DAS181 program.
View full company profile